Specialized Research Khavinson Bioregulator

Pancragen

Also known as: Peptídeo pancreático

Molecular Identifiers

Molecular Formula

C26H37N7O8

PubChem CID

68451868

Molecular Weight

563.58 Da

Overview

Pancreatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in pancreatic cells and supports beta cell function. Used in short cycles for pancreatic function protection and support.

Sequence (1 letter): KEDW
Extended notation: Lys-Glu-Asp-Trp

Half-life

~2-4 hours

Administration Route

Subcutaneous or intramuscular

Category

Specialized Research

Mechanism of Action

  • Regulation of gene expression in pancreatic cells
  • Support for beta cell function and viability
  • Normalization of insulin secretion
  • Modulation of pancreatic glycemic metabolism
  • Bioregulatory effect on endocrine and exocrine pancreas

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 5-10 mg per day via subcutaneous injection
Frequency Once daily
Timing Morning or as per protocol
Duration 10-20 days, cycled 2-4 times per year

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site pain
  • Local redness (rare)

Presentations & Preparation

Vials of Pancragen found in the research market:

20 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per vial
  • Inject the diluent slowly against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on Pancragen.

2013 · Bull Exp Biol Med

Effects of pancragen on the differentiation of pancreatic cells during their ageing

Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV, Tarnovskaya SI
2015 · Adv Gerontol

Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys

Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VKh

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily